Trademarkia Logo

Canada

C$
Trademark Search in Canada
EMGALITY AND DESIGN

View On IC.GC.CA

EMGALITY AND DESIGN
REGISTERED

on 8 Jan 2020

Last Applicant/ Owned by

ELI LILLY AND COMPANY

Lilly Corporate CenterIndianapolis, IN 46285

US

Serial Number

1864838 filed on 26th Oct 2017

Registration Number

TMA1068523 registered on 8th Jan 2020

Registration expiry Date

8th Jan 2030

Correspondent Address

BORDEN LADNER GERVAIS LLP

World Exchange Plaza100 Queen Street, Suite 1300Ottawa

ONTARIO

CA

K1P1J9

EMGALITY AND DESIGN

Trademark usage description

pharmaceutical preparations namely pharmaceutical preparations for the treatment of alzheimer's disease, anxiety disorders, atopic dermatitis, autoimm Read More

Vienna Information

25 . 7 . 1

Surfaces or backgrounds covered with repeated geometrical figures or designsSurfaces ou fonds couverts de figures ou de motifs géométriques répétés

25 . 7 . 7

Surfaces or backgrounds covered with dotsSurfaces ou fonds couverts de points

25 . 7 . 6

Surfaces or backgrounds covered with circles or ellipsesSurfaces ou fonds couverts de cercles ou d'ellipses

26 . 11 . 1

One line or one bandUne ligne ou une bande

26 . 11 . 13

Wavy lines or bands, zigzag lines or bandsLignes ou bandes ondulées, en dents de scie

26 . 11 . 14

Dotted lines or bandsLignes ou bandes pointillées

Classification Information

Class [005]
Pharmaceutical preparations namely pharmaceutical preparations for the treatment of Alzheimer's disease, anxiety disorders, atopic dermatitis, autoimmune diseases and disorders, axial spondyloarthritis, bone and skeletal diseases and disorders namely osteoporosis, osteoarthritis, fracture healing, bone frailty due to extended ventilator use, hip replacement surgery and knee replacement surgery, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries, arthritis, bursitis, tendonitis, osteonecrosis and Paget's disease, cancer, cardiovascular diseases, central nervous system diseases and disorders namely, anxiety disorders, depression, bipolar depression, bipolar disorder, treatment resistant depression, schizophrenia and cognitive impairment associated with schizophrenia, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders namely psoriasis, skin cancer and eczema, diabetes, dyslipidemia, endocrine diseases and disorders, namely Type 2 Diabetes Mellitus and Type 1 Diabetes Mellitus, gastrointestinal diseases and disorders, hypoglycemia, inflammation and inflammatory diseases and disorders namely inflammatory bowel diseases, inflammatory connective tissue diseases and rheumatoid arthritis, kidney diseases and disorders, liver diseases and disorders, mental diseases and disorders, namely mood disorders, schizophrenia, cognitive and bipolar disorders, epilepsy, and cerebral palsy, metabolic diseases and disorders namely metabolic syndrome, migraines, multiple sclerosis, muscle diseases and disorders namely myopathies, chronic fatigue syndrome, fibromyalgia and muscular dystrophy, neurodegenerative diseases and disorders namely Huntington's disease, Alzheimer's disease, and dementia, neurological disorders namely Alzheimer's disease, mild cognitive impairment, Parkinson's disease and multiple sclerosis, pain relief, Parkinson's disease, psoriatic arthritis, rheumatoid arthritis, Sjogren's syndrome, sleep disorders, spondyloarthropathy, systemic lupus erythematosus, ulcerative colitis; Diagnostic reagents for medical diagnostic use; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative diseases

Classification kind code

11

Class [044]
Medical information services in the field of central nervous systems diseases and disorders

Classification kind code

11

Mark Details

Serial Number

1864838

Mark Type

Trademark

Legal History

Show more

Action TakenStatus
Submitted for opposition 190
on 31st Jul 2019		Registration Pending
Submitted for opposition 191
on 31st Jul 2019		Registration Fee Notice Sent
Submitted for opposition 42
on 8th May 2019		Advertised
Submitted for opposition 26
on 18th Apr 2019		Approved
Submitted for opposition 27
on 1st Mar 2019		Approval Notice Sent
Submitted for opposition 22
on 3rd Jan 2019		Search Recorded
Submitted for opposition 20
on 3rd Jan 2019		Examiner's First Report
Submitted for opposition 1
on 27th Oct 2017		Created
Submitted for opposition 31
on 27th Oct 2017		Formalized
Submitted for opposition 30
on 26th Oct 2017		Filed